Signalling diversity and subtype selectivity of serotonergic psychedelics

As interest in psychedelic therapeutics continues to grow, understanding how these compounds interact with the serotonergic system is becoming increasingly important. While the 5-HT_2A receptor is the primary target associated with psychedelic activity, many compounds also engage additional serotonin receptor subtypes that may influence both therapeutic outcomes and safety profiles.

Looking beyond a single receptor

Developing next-generation psychedelic therapies requires a deeper understanding of receptor selectivity, intrinsic efficacy, and downstream signaling. Differences in how compounds activate signaling pathways have been proposed as a key factor in separating desired therapeutic effects from unwanted hallucinogenic activity.

A comprehensive pharmacology platform

To address this challenge, Sygnature Discovery has established an integrated suite of cell-based assays designed to characterize serotonergic compounds across multiple signaling pathways and receptor subtypes. The platform combines:

• Calcium mobilization assays
• IP₁ accumulation assays
• β-arrestin2 recruitment assays
• Phospho-ERK pathway analysis
• Profiling across 5-HT_1A, 5-HT_2A, 5-HT_2B, 5-HT_2C, 5-HT₆, and 5-HT₇ receptors

Together, these capabilities provide a more complete view of compound pharmacology, enabling researchers to assess both signaling behavior and receptor selectivity within a single framework.

Supporting smarter drug discovery decisions

By comparing hallucinogenic and non-hallucinogenic serotonergic compounds across multiple assays, this work demonstrates how integrated pharmacology profiling can generate valuable insights earlier in discovery. Understanding efficacy, potency, and subtype activity can help teams identify promising candidates, better assess risk, and guide optimization strategies with greater confidence.

Download the poster to explore how Sygnature Discovery is using a multi-assay, multi-receptor approach to characterize serotonergic psychedelics and support the development of next-generation therapies.